To assess the association of semaglutide with incident CUD, the study population included 587,849 patients with T2D who had active medical encounters for T2D during 12/20175/2021, were for the first time prescribed semaglutide (Ozempic) or non-GLP1-1RA anti-diabetes medications (new-user design) during 12/20175/2021(index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Recent Findings GLP-1 RAs modulate insulin signaling, reduce neuroinflammation and oxidative stress, and improve mitochondrial functional mechanisms linked to neuroprotection
It names subtherapeutic drug exposure, breakthrough hyperglycemia or weight regain, and unpredictable side-effect patterns
We have written more about formaldehyde-releasing preservatives and the concerns around them at Dmdm Hydantoin, but do not get too scared, those are more theories than proven facts
2026 Ozempic NAION Lawsuit Updates March 3, 2026 Update: The judge overseeing the federal GLP-1 vision loss litigation selected a group of plaintiffs attorneys to manage discovery and other coordinated pretrial matters involving claims that Ozempic, Wegovy and similar drugs caused permanent vision damage
It then asks why well-powered trials have largely failed where smaller studies and real-world data succeeded, with attention to brain exposure, trial design, and patient selection, and outlines what the next generation of studies will need to test the hypothesis properly